Compare ALK-Abello A/S with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
DKK 44,877 Million ()
40.00
NA
14.44%
0.06
18.57%
6.96
Revenue and Profits:
Net Sales:
1,733 Million
(Quarterly Results - Dec 2025)
Net Profit:
266 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.16%
0%
-22.16%
6 Months
-22.16%
0%
-22.16%
1 Year
-6.26%
0%
-6.26%
2 Years
9.19%
0%
9.19%
3 Years
27.44%
0%
27.44%
4 Years
47.77%
0%
47.77%
5 Years
67.22%
0%
67.22%
ALK-Abello A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.58%
EBIT Growth (5y)
61.38%
EBIT to Interest (avg)
21.07
Debt to EBITDA (avg)
0.46
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.99
Tax Ratio
23.26%
Dividend Payout Ratio
29.61%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
11.38%
ROE (avg)
8.32%
Valuation key factors
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
7.36
EV to EBIT
28.09
EV to EBITDA
23.44
EV to Capital Employed
8.57
EV to Sales
7.36
PEG Ratio
0.85
Dividend Yield
13.66%
ROCE (Latest)
30.50%
ROE (Latest)
18.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
1,733.00
1,499.00
15.61%
Operating Profit (PBDIT) excl Other Income
481.00
281.00
71.17%
Interest
0.00
7.00
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
266.00
170.00
56.47%
Operating Profit Margin (Excl OI)
222.70%
136.80%
8.59%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 15.61% vs 11.45% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 56.47% vs 21.43% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
6,312.00
5,537.00
14.00%
Operating Profit (PBDIT) excl Other Income
1,981.00
1,360.00
45.66%
Interest
23.00
62.00
-62.90%
Exceptional Items
-10.00
-6.00
-66.67%
Consolidate Net Profit
1,197.00
815.00
46.87%
Operating Profit Margin (Excl OI)
263.50%
197.60%
6.59%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.00% vs 14.78% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 46.87% vs 67.70% in Dec 2024
About ALK-Abello A/S 
ALK-Abello A/S
Pharmaceuticals & Biotechnology
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Company Coordinates 
Company Details
Boege Alle 1 , HOERSHOLM None : 2970
Registrar Details






